Male Breast Cancer Completed Phase 1 / 2 Trials for Cefotaxime (DB00493)

IndicationStatusPhase
DBCOND0028546 (Male Breast Cancer)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00331552Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast CancerTreatment
NCT00470301Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast CancerTreatment